The agenda for the 17 June 2015 TC meeting is now available. The Commission will consider the following technologies:

• Fibrinogen (human) with thrombin (human) (Evarrest) - new blood product
• Fibrinogen (human) with aprotonin and coagulation factor XIII and thrombin (human) and calcium chloride (Tisseel) - new blood product
• Eribulin mesylate (Halaven) - new indication
• Denosumab (Xgeva) - new indication
• Biscodyl (Dulcolax) - new medicine
• Coagulation factor XIII (recombinant) (Kogenate) - review of SMR
• Octacog alfa (Helixate Nexgen) - review of SMR

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-06/odj_ct_17062015_internet.pdf [French]